Chunyi Hao

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. · The Lancet · 2023 · 891 citations · Full text

Urology, Surgical Oncology, Gastrointestinal Oncology +5

Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution

Shaoping Ling, Zheng Hu, Zuyu Yang et al. · Proceedings of the National Academy of Sciences · 2015 · 370 citations · Full text

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 364 citations

Oncology, Hepatology, Medicine +10

Proteome Analysis of Hepatocellular Carcinoma by Two-dimensional Difference Gel Electrophoresis

Wei Sun, Baocai Xing, Yi Sun et al. · Molecular & Cellular Proteomics · 2007 · 245 citations · Full text

Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

Shukui Qin, Zhendong Chen, Weijia Fang et al. · Journal of Clinical Oncology · 2022 · 174 citations · Full text